Portal de Periódicos da CAPES

Plasma Epstein‐Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States

2007; Wiley; Volume: 136; Issue: 6 Linguagem: Inglês

10.1016/j.otohns.2006.11.053

1097-6817

Mazurczak-Pluta Teresa, Guopei Yu, Kenneth S. Hu, James C. L. Li,

Polyomavirus and related diseases

Objective To examine the Epstein‐Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population. Study Design and Setting Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed. Results Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent. Conclusion NPC screening in a high‐risk, nonendemic population using EBV‐specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy. Significance The development of a cost‐effective NPC screening strategy in a high‐risk, nonendemic population in the United States. © 2007 American Academy of Otolaryngology‐Head and Neck Surgery Foundation. All rights reserved.